Integrin receptor antagonists
US5710159A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 9, 1996 |
| Grant date | Jan 20, 1998 |
| Priority date | — |
| Expiry date | May 9, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to novel heterocycle compounds including but not limited to 3-3-3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.